Tirzepatide
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound) studied for type 2 diabetes and chronic weight management, with extensive Phase 3 trial data.
Overview
Tirzepatide is a synthetic peptide that activates two receptors involved in metabolic signaling: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual-receptor mechanism distinguishes it from single-target GLP-1 receptor agonists. Tirzepatide is manufactured by Eli Lilly and is administered as a once-weekly subcutaneous injection.
As a dual agonist, tirzepatide works by mimicking the activity of two naturally occurring incretin hormones that the body releases in response to food intake. These hormones help regulate blood sugar, slow gastric emptying, and influence appetite signaling in the brain. Tirzepatide has been one of the most widely studied peptides in metabolic research in recent years and has received multiple regulatory approvals in the United States.
Research context
Tirzepatide has been studied across several large-scale clinical trial programs. The SURPASS series evaluated its effects in adults with type 2 diabetes, while the SURMOUNT series studied its effects in adults with obesity or overweight. Key areas of clinical investigation include metabolic health and glycemic control in type 2 diabetes, body weight management in adults with obesity or overweight (with or without type 2 diabetes), obstructive sleep apnea in adults with obesity, and cardiovascular risk factors associated with excess body weight.
Phase 3 trials in the SURMOUNT program enrolled thousands of participants and evaluated tirzepatide at multiple dose levels over periods up to 72 weeks. Head-to-head trials have also compared tirzepatide with other approved medications in the same therapeutic class. The SURMOUNT-OSA trial specifically examined breathing-related outcomes during sleep in adults with obesity and moderate-to-severe obstructive sleep apnea.
Safety and regulatory framing
FDA-approved as Mounjaro (T2D) and Zepbound (weight management, OSA)
Tirzepatide is an FDA-approved prescription medication in the United States. It is marketed under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity). Both formulations require a prescription and are administered by subcutaneous injection.
As with all prescription medications, tirzepatide carries labeled warnings and potential side effects, which are described in its FDA-approved prescribing information. Regulatory status and product availability vary by country. Tirzepatide is not available as an oral formulation in any FDA-approved product as of early 2026. Readers should consult a licensed healthcare provider for any decisions related to treatment.
References
- SURMOUNT-1 Phase 3 Trial ↗ClinicalTrials.gov
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM (2022) ↗New England Journal of Medicine
- FDA Press Release: Approval of Zepbound for Chronic Weight Management (2023) ↗FDA.gov
- Mounjaro (Tirzepatide) Prescribing Information — FDA Label ↗FDA.gov
- SURMOUNT-OSA Trial ↗ClinicalTrials.gov
Research information only
Peptide Daily is an informational resource only. Peptide research chemicals are not approved for human use by the FDA unless otherwise noted. Nothing on this site constitutes medical advice. Consult a qualified healthcare provider before using any peptide or research chemical.
New regulatory shifts matter as much as the peptide itself
Subscribe for editorial updates when major price moves, lab tests, or regulatory events affect the compounds you're tracking.
Weekly update
Get weekly peptide price intel
No spam, unsubscribe anytime.
Keep exploring the research context
Semaglutide
Semaglutide is an FDA-approved GLP-1 receptor agonist (Ozempic, Wegovy) with robust clinical evidence for type 2 diabetes management and chronic weight loss.
Retatrutide
Retatrutide is an investigational triple GLP-1/GIP/glucagon receptor agonist in Phase 3 TRIUMPH trials, demonstrating significant weight reduction in Phase 2 research.
Mazdutide
Mazdutide is a dual GLP-1/glucagon receptor agonist approved in China for weight management and T2D; currently in Phase 2 US trials. Not FDA-approved.